News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - Amicus Therapeutics, Inc. (FOLD), a biotechnology company, on Monday reported higher preliminary revenue for fiscal 2023.
Yearly revenue increased 21 percent to around $399.4 million from $329 million.
Sequentially, revenue increased to around $399.4 million from $115.1 million in the fourth quarter.
The pharma firm's lead drug Galafold recorded a net sale of around $387.8 million representing a year-over-year increase of 18 percent.
Further, the company said it sees delivering double-digit Galafold revenue growth in the range of 11 percent to 16 percent at constant exchange rates for the full year.
On Friday, Amicus shares closed at $13.75, up 1.70% on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services..
E-mail: 24_support@just2trade.online
